^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFRvIII mutation

    i
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    CARv3-TEAM-E T Cells in Glioblastoma (NCT05660369)
    Phase 1
    Marcela V. Maus, M.D.,Ph.D.
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    03/22/2023
    Primary completion :
    06/01/2025
    Completion :
    06/01/2026
    MGMT
    |
    EGFR amplification • EGFRvIII mutation
    |
    CARv3-TEAM-E T cells
    A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) (NCT02573324)
    Phase 3
    AbbVie
    Completed
    Last update posted :
    05/11/2023
    Initiation :
    01/04/2015
    Primary completion :
    04/04/2022
    Completion :
    04/04/2022
    EGFR • MGMT
    |
    EGFR mutation • EGFR amplification • EGFRvIII mutation
    |
    temozolomide • depatuxizumab mafodotin (ABT-414)
    Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (RTOG Foundation 3508) (NCT02343406)
    Phase 2
    AbbVie
    Completed
    Last update posted :
    05/22/2020
    Initiation :
    02/17/2015
    Primary completion :
    06/24/2019
    Completion :
    06/24/2019
    EGFR
    |
    EGFR mutation • EGFR amplification • EGFRvIII mutation
    |
    temozolomide • lomustine • depatuxizumab mafodotin (ABT-414)
    Expanded Access to ABT-414 (NCT03123952)
    Phase N/A
    AbbVie
    No Longer Available
    Last update posted :
    07/15/2019
    EGFR
    |
    EGFR mutation • EGFR amplification • EGFRvIII mutation
    |
    depatuxizumab mafodotin (ABT-414)